PFE Pfizer Inc.

36.34
-0.16  -0%
Previous Close 36.5
Open 36.63
Price To Book 3.37
Market Cap 200,998,297,148
Shares 5,531,048,353
Volume 13,722,476
Short Ratio 2.28
Av. Daily Volume 21,510,865
Stock charts supplied by TradingView

NewsSee all news

  1. ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology

    LOS ANGELES, Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (NYSE:AZN),

  2. Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis

    –Abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study– –Findings follow recent positive top-line results for second abrocitinib Phase 3 pivotal study, JADE MONO-2– Pfizer Inc. (NYSE:PFE)

  3. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive

  4. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that

  5. Checkmate Pharmaceuticals Announces Dosing of First Patient in a Phase 1b/2 Study in Squamous Cell Carcinoma of the Head and Neck with Lead Investigational Candidate CMP-001

    CMP-001, a TLR9 Agonist, to be Evaluated in Combination with BAVENCIO®; with or without Utomilumab, a 4-1BB Agonist, and PF-04518600, an OX40 Agonist Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 data released May 15, 2019 met primary endpoints.
PF-04965842 - abrocitinib
Moderate-to-severe atopic dermatitis (AD)
Approval announced December 13, 2017.
IXIFI
Remicade (infliximab) biosimilar
Phase 3 data released November 28, 2017 - primary endpoint not met.
Avelumab
Gastric cancer
Approval announced October 12, 2017.
LYRICA (pregabalin)
Postherpetic neuralgia (PHN)
Advisory Committee Meeting held November 7, 2017. No votes cast.
Staphylococcus aureus vaccine
Phase 3 data presented at ESMO 2017 - Overall survial HR=0.760 (p=0.09)
XALKORI (crizotinib)
ALK-positive advanced non-small cell lung cancer(NSCLC)
Approval announced September 1, 2017.
Mylotarg (gemtuzumab ozogamicin)
Acute myeloid leukemia (AML)
CRL issued June 22, 2017.
Epoetin alfa biosimilar
FDA approval announced November 2, 2018.
Lorlatinib
ALK+ NSCLC
Approval announced May 9, 2017.
Avelumab
Urothelial Carcinoma
Approval announced August 17, 2017.
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
PDUFA date under priority review 4Q 2019.
XTANDI (ARCHES)
Metastatic hormone sensitive prostate cancer
Phase 3 trial terminated - noted May 17, 2017.
XTANDI (ENDEAR)
Triple negative breast cancer
Phase 3 data due 2H 2020.
XTANDI (EMBARK)
Non-metastatic high risk hormone-sensitive prostate cancer
FDA approval announced July 13, 2018.
XTANDI (PROSPER)
Non-metastatic high risk hormone-sensitive prostate cancer
Approval announced May 30, 2018.
Xeljanz
Ulcerative colitis
Approval announced December 14, 2017.
Xeljanz
Psoriatic arthritis
FDA Approval announced October 16, 2018.
Talazoparib
BRCA-mutated breast cancer
Approval announced 16 November, 2017.
Sutent (Sunitinib)
Renal cell carcinoma (RCC)
Phase 3 trial met primary endpoint - December 2016.
LYRICA (pregabalin)
Pediatric Epilepsy
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Approval announced December 19, 2017.
BOSULIF (BOSUTINIB)
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Priority review announced November 29, 2016. Approval announced March 23, 2017.
Avelumab
Metastatic Merkel cell carcinoma
sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017.
IBRANCE (palbociclib)
HR+, HER2- Metastatic Breast Cancer
Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.
Tanezumab
Chronic low back pain
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met. Data from trial April 18, 2019 met 2/3 primary endpoints in 5mg arm but failed to meet endpoints in 2.5mg arm. Regulatory filing due 4Q 2019 or early 2020.
Tanezumab
Osteoarthritis
Phase 3 ongoing.
Tanezumab
Cancer pain
Approval announced June 27, 2018.
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
Phase 3 trial enrolling - November 2018.
ARRY 797
LMNA A/C-related dilated cardiomyopathy (DCM)
Phase 3 data failed to meet endpoints - August 2, 2019.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Approved Sept 10 2014
XTANDI
Cancer - mCRPC who have not received chemotherapy
Phase 3 data presented July 6, 2019. OS 9.0 months vs. 5.4 months for control (HR 0.52), ORR 26% vs. 1.9%.
Encorafenib and cetuximab - BEACON CRC
BRAF-Mutant Colorectal Cancer
FDA Approval announced May 6, 2019.
Tafamidis (tafamidis free acid form)
Transthyretin amyloid cardiomyopathy (ATTR-CM)
FDA Approval announced September 27, 2018.
Dacomitinib
Non-small cell lung cancer (NSCLC)
Phase 3 trial discontinued due to futility.
INLYTA (axitinib)
Recurrent renal cell carcinoma (RCC)
Phase 1b data June 28, 2019 noted safety concerns. Phase 3 trial to commence 1H 2020.
PF-06939926
Duchenne muscular dystrophy (DMD)
Phase 3 overall survival secondary endpoint not met - June 25, 2018. PFS primary endpoint met (announced previously).
IBRANCE - PALOMA-3
Breast cancer
Phase 3 presentation at ASCO June 2018.
IBRANCE (palbociclib)
Head and neck squamous cell carcinoma
FDA approval announced November 21, 2018.
Glasdegib
Acute myeloid leukemia (AML)
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B
Phase 2 development terminated due to lack of efficacy.
Domagrozumab
Duchenne muscular dystrophy (DMD)
FDA Approval announced May 14, 2019.
BAVENCIO (avelumab) and INLYTA (axitinib)
Renal cell carcinoma (RCC)
FDA approval announced April 22, 2019.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
FDA Approval March 11, 2019.
PF-05280014 TRAZIMERA
Herceptin biosimilar
Phase 3 trial to be terminated due to lack of efficacy.
Avelumab - JAVELIN Ovarian 100
Ovarian cancer
Phase 3 data due 2H 2021.
PF-06651600 - JAK3
Alopecia areata
FDA approval announced May 6, 2019.
Tafamidis
Transthyretin amyloid cardiomyopathy (ATTR-CM)
FDA approval of sNDA announced April 4, 2019.
IBRANCE (palbociclib)
HR+/HER2- advanced breast cancer in men
Phase 3 data due 2H 2020.
IBRANCE (palbociclib) - PENELOPE
Early stage breast cancer
Phase 3 data due 2H 2020.
IBRANCE (palbociclib) - PALLAS
Early stage breast cancer
Phase 3 data due 1H 2020.
Avelumab - Bavencio
Gastric cancer
Phase 3 data due 1H 2020.
Avelumab - Bavencio
Urothelial Cancer
Phase 3 data due 2H 2020.
PF-06425090
C. difficile Infection
Phase 3 data released May 24, 2019 did not meet primary endpoint.
LYRICA (pregabalin)
Primary generalized tonic-clonic (PGTC) seizures - epilepsy
FDA Approval announced June 28, 2019.
PF-06439535
Biosimilar bevacizumab
Phase 3 trial did not meet primary endpoint - June 28, 2019.
Sildenafil and inhaled nitric oxide (iNO)
Persistent Pulmonary Hypertension (PPHN)
FDA approval announced July 23, 2019.
Ruxience (Biosimilar to Rituxan)
CD20-positive, low tumor burden, follicular lymphoma.
Phase 3 trial met primary and secondary endpoints - September 27, 2019.
Abrocitinib
Atopic Dermatitis

Latest News

  1. ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology

    LOS ANGELES, Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (NYSE:AZN),

  2. Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis

    –Abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study– –Findings follow recent positive top-line results for second abrocitinib Phase 3 pivotal study, JADE MONO-2– Pfizer Inc. (NYSE:PFE)

  3. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive

  4. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that

  5. Checkmate Pharmaceuticals Announces Dosing of First Patient in a Phase 1b/2 Study in Squamous Cell Carcinoma of the Head and Neck with Lead Investigational Candidate CMP-001

    CMP-001, a TLR9 Agonist, to be Evaluated in Combination with BAVENCIO®; with or without Utomilumab, a 4-1BB Agonist, and PF-04518600, an OX40 Agonist Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical

  6. Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

    Three of six patients showed durable responses (patients treated with the recommended Phase 2 dose)1 Combination therapy results in changes in tumor microenvironment shifting immune status from "cold" to "hot"

  7. Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

  8. Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer

    - Results to be presented during a late-breaking oral session at the 2019 ESMO Congress and simultaneously published in The New England Journal of Medicine – - As previously announced, BRAFTOVI combinations showed

  9. Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology

    Pfizer Inc. (NYSE:PFE) and Flatiron Health today announced an expanded strategic collaboration to further integrate and increase the use of real-world data in Pfizer's development of innovative targeted cancer

  10. Pfizer Inc. Awards "Golden Tickets" to Neutrolis and Mediar Therapeutics

    Winners of the Pfizer Golden Ticket Program announced last night during a panel discussion and networking event at Pfizer's Cambridge, MA R&D site Pfizer Inc. and LabCentral announced that Pfizer has selected

  11. Ian Read to Retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman

    Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to retire on December 31, 2019, and that it has

  12. Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

    –Study achieves all co-primary and key secondary endpoints– –Safety results show both doses of abrocitinib consistent with prior clinical trial experiences– Pfizer Inc. (NYSE:PFE) announced today positive top-line

  13. New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019

    Analyses from the Phase III JAVELIN Renal 101 study support efficacy of BAVENCIO plus axitinib across multiple subgroups of patients with advanced renal cell carcinoma (RCC) Abstracts highlight data on BAVENCIO as a

  14. Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology

    Pfizer Inc. (NYSE:PFE) and Flatiron Health today announced an expanded strategic collaboration to further integrate and increase the use of real-world data in Pfizer's development of innovative targeted cancer

  15. Pfizer Declares Fourth-Quarter 2019 Dividend

    Board of Directors approves quarterly cash dividend to $0.36 per share The Board of Directors of Pfizer Inc. today declared a 36-cent fourth-quarter 2019 dividend on the company's common stock, payable December 2,

  16. CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

    ROCKLAND, MA and NEW YORK, US, September 20, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE:PFE) today announced that the

  17. Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio

    Presentations of interest include a late-breaking abstract on expanded Phase 3 data in BRAF-mutant metastatic colorectal cancer Pfizer Inc. (NYSE:PFE) is presenting data across its industry-leading oncology portfolio,

  18. Biotech Companies Endeavor to Address Global Health Issues

    NEW YORK, Sept. 18, 2019 /PRNewswire/ -- The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report

  19. Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call With Analysts

    Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 29, 2019. The purpose of the call is to provide an

  20. Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants

    Pfizer Inc. (NYSE:PFE) announced positive preliminary results following administration of three doses in a four-dose series for a Proof-of-Concept Phase 2 study (B7471003) to assess safety and immunogenicity of its

  21. Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants

    Additionally, Pfizer Has Completed Enrollment of its Phase 3 Studies (NCT03828617, NCT03835975 and NCT03760146) for its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of

  22. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Chief Financial Officer and Executive Vice President, Global Supply and Business Operations, at the Morgan

  23. ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

    ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive headline results from its global phase III ATLAS-2M study of the

  24. U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

    TOKYO & Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review

  25. ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months

    ATLAS-2M study met its primary endpoint, showing similar efficacy of cabotegravir and rilpivirine administered every eight weeks compared to four-week administration ViiV Healthcare, the global specialist HIV company